SCHEMBL20181601

SCHEMBL20181601

CCc1nn2ccccc2c1C(=O)c1ccc(OC)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.48
LMNA P02545 2/20 0.48
CNR2 P34972 3/20 0.45
EGFR P00533 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 3/20 0.43
ALOX15 P16050 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KMT2A Q03164 2/20 0.43
CYP2C9 P11712 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GAA P10253 3/20 0.42
MGAM O43451 2/20 0.42
AMY1A P0DUB6 2/20 0.42
SI P14410 2/20 0.42
MGAM2 Q2M2H8 2/20 0.42
F12 P00748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20181600 0.86 MIF (0.43) LMNAEGFRALDH1A1ALOX15NPSR1
SCHEMBL38666633 0.80 EGFR (0.48) EGFRKDM4EALDH1A1NPSR1KMT2A
SCHEMBL3210946 0.80 KMT2A (0.62) POLBLMNACNR2KDM4EALDH1A1
SCHEMBL5847756 0.78 MIF (0.48) EGFRKDM4EALDH1A1ALOX15NPSR1
SCHEMBL2035471 0.78 EGFR (0.48) POLBLMNAEGFRKDM4EALDH1A1
SCHEMBL683926 0.77 MIF (0.50) LMNAEGFRKDM4EALDH1A1ALOX15
SCHEMBL20181603 0.77 SLC22A12 (0.46) POLBLMNAEGFRALDH1A1NPSR1
SCHEMBL1780786 0.76 EGFR (0.53) POLBEGFRKDM4EALDH1A1NPSR1
SCHEMBL24288758 0.74 EGFR (0.36) EGFRKDM4EALDH1A1NPSR1KMT2A
SCHEMBL8878630 0.74 EGFR (0.48) CNR2EGFRALDH1A1NPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50083-E1 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2024-08-20 US disclosed
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 US disclosed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 US disclosed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 US disclosed
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-08-20 US disclosed
EP-3632904-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2020-04-08 EP disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
EP-3543240-A1 URAT1 INHIBITOR AND USE THEREOF Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
WO-2018090921-A1 URAT1 INHIBITOR AND USE THEREOF 江苏新元素医药科技有限公司 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 POLB 3944/4885LMNA 3692/4885CNR2 3257/4885
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF SLC14A1, SLC10A6, SLC10A1 POLB 4150/4885LMNA 3241/4885CNR2 3886/4885
US-10875865-B2 URAT1 inhibitor and use thereof SLC14A1, SLC10A6, SLC10A1 POLB 4150/4885LMNA 3241/4885CNR2 3886/4885
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION SLC10A6, SLC10A1, SLC28A1 POLB 3944/4885LMNA 3692/4885CNR2 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.